Press release content from Business Wire. The AP news staff was not involved in its creation.
Independent Bank Corp. and Rockland Trust Company Appoint Warren Fields and James O’Shanna Morton to Board of Directors
January 21, 2021 GMT
ROCKLAND, Mass. (BUSINESS WIRE) Jan 21, 2021
Independent Bank Corp. (Nasdaq Global Select Market: INDB), parent of Rockland Trust Company, today announced the appointment of Warren Fields and James O’Shanna Morton to its Board of Directors. Rockland Trust also simultaneously appointed Mr. Fields and Mr. Morton to its Board of Directors. Each of the appointments will be effective February 1, 2021.
ADVERTISEMENT
Warren Fields
Patria Investments Limited Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
GRAND CAYMAN, Cayman Islands, Jan. 22, 2021 /PRNewswire/ Patria Investments Limited ( Patria ), one of the leading private markets investment firms in Latin America, today announced the pricing of its initial public offering of 30,098,824 Class A common shares, consisting of 16,650,000 Class A common shares offered by Patria and 13,448,824 Class A common shares offered by the selling shareholder, Blackstone PAT Holdings IV, L.L.C., pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission ( SEC ) at a public offering price of $17.00 per share. The Class A common shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol PAX today and the offering is expected to close on January 26, 2021, subject to customary closing conditions.
/PRNewswire/ Trinity Capital Inc. ("Trinity"), an internally managed business development company, today announced that it has commenced an initial public.
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial
Calliditas Therapeutics AB (publ) ( Calliditas ) (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the global Phase 3 clinical trial NefIgArd, which investigates the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN).
The NefIgArd trial consists of two parts: Part A and Part B. Part A, which forms the basis for potential regulatory submissions and approvals, provided data on the efficacy and safety of Nefecon. Calliditas read out positive topline data from Part A of the trial on 8 November 2020, announcing that the study met its primary endpoint, reduction in proteinuria, and key secondary endpoint stabilization of eGFR. It also showed that Nefecon was generally well-tolerated.
Iridium Partner MetOcean Telematics Provides Search & Rescue Buoys to the United States Coast Guard
Iridium Communications Inc. (Nasdaq: IRDM) is proud to share that exclusive Iridium partner MetOcean Telematics has been awarded a five-year blanket purchase agreement (BPA) to supply the United States Coast Guard (USCG) with its Search and Rescue (SAR) buoy, the Iridium Self Locating Datum Marker Buoy (iSLDMB™). A critical tool for SAR events, the innovative, rugged, and compact buoy is designed and tested to meet the stringent performance requirements of coast guards around the world.
The iSLDMB plays a useful role in adding additional safety and protection for USCG personnel. During an active SAR event, USCG aircraft can quickly deploy the buoys across the vast ocean territory to their targeted location by air. When the buoy hits the water, its suite of sensors monitor the first meter below sea level of the surrounding area and can detect objects, surface temperature, and provid